Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

Eye (Basingstoke)

Volumn 30, Issue 3, 2016, Pages 463-472

  Olmos, L C ^a,b   Sayed, M S ^a   Moraczewski, A L ^a,c   Gedde, S J ^a   Rosenfeld, P J ^a   Shi, W ^a   Feuer, W J ^a   Lee, R K ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Ophthalmology Assoc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; CASE STUDY; CATARACT; CATARACT EXTRACTION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; EROSION; FEMALE; FOLLOW UP; GLAUCOMA DRAINAGE IMPLANT; GLAUCOMA SURGERY; HUMAN; HYPHEMA; INTRAOCULAR PRESSURE; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEOVASCULAR GLAUCOMA; OUTCOME ASSESSMENT; PANRETINAL PHOTOCOAGULATION; PARS PLANA VITRECTOMY; RETINA DETACHMENT; RETROSPECTIVE STUDY; VISUAL ACUITY; VITRECTOMY; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; GLAUCOMA, NEOVASCULAR; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; ANGIOGENESIS INHIBITORS; ANTIHYPERTENSIVE AGENTS; BEVACIZUMAB; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, NEOVASCULAR; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; LASER COAGULATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85014820603     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2015.259     Document Type: Article

References (46)

1. John T, Sassani JW, Eagle RC Jr. The myofibroblastic component of rubeosis iridis. Ophthalmology 1983; 90(6): 721-728.
2. Shazly TA. Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 2009; 24(2): 113-121.
3. Gartner S, Henkind P. Neovascularization of the iris (rubeosis iridis). Surv Ophthalmol 1978; 22(5): 291-312.
4. Brown GC, Magargal LE, Schachat A, Shah H. Neovascular glaucoma. Etiologic considerations. Ophthalmology 1984; 91(4): 315-320.
5. Olmos LC, Lee RK. Medical and surgical treatment of neovascular glaucoma. Int Ophthalmol Clin 2011; 51(3): 27-36.
6. Cashwell LF, Marks WP. Panretinal photocoagulation in the management of neovascular glaucoma. South Med J 1988; 81(11): 1364-1368.
7. Hayreh SS, Klugman MR, Podhajsky P, Servais GE, Perkins ES. Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study. Graefes Arch Clin Exp Ophthalmol 1990; 228(4): 281-296.
8. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001; 108(10): 1767-1776.
9. Doft BH, Blankenship G. Retinopathy risk factor regression after laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1984; 91(12): 1453-1457.
10. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118(4): 445-450.
11. Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994; 112(11): 1476-1482.
12. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331(22): 1480-1487.
13. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol 1996; 80(3): 241-245.
14. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002; 120 (12): 1644-1650.
15. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114(1): 66-71.
16. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007; 12(6): 713-718.
17. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Retina 2006; 26(5): 495-511.
18. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007; 114(4): 743-750.
19. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27(2): 141-149.
20. Kiddee W, Orapiriyakul L, Kittigoonpaisan K, Tantisarasart T, Wangsupadilok B. Efficacy of adjunctive subconjunctival bevacizumab on the outcomes of primary trabeculectomy with mitomycin C: a prospective randomized placebo-controlled trial. J Glaucoma 2015; 24(8): 600-606.
21. Van Bergen T, Vandewalle E, Moons L, Stalmans I. Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery. Acta Ophthalmol 2015; 93: 667-678.
22. Moraczewski AL, Lee RK, Palmberg PF, Rosenfeld PJ, Feuer WJ. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol 2009; 93(5): 589-593.
23. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006; 26(3): 354-356.
24. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142(6): 1054-1056.
25. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006; 37(2): 144-146.
26. Mason JO 3rd, Albert MA Jr., Mays A, Vail R.. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 2006; 26(7): 839-841.
27. Silva Paula J, Jorge R, Alves Costa R, Rodrigues Mde L, Scott IU. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 2006; 84(4): 556-557.
28. Gheith ME, Siam GA, de Barros DS, Garg SJ, Moster MR. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007; 23(5): 487-491.
29. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol 2007; 35(5): 494-496.
30. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115(9): 1571-1580. 1580.e1-e3.
31. Anderson DM, Morin JD, Hunter WS. Rubeosis iridis. Can J Ophthalmol 1971; 6(3): 183-188.
32. Duker JS, Brown GC. The efficacy of panretinal photocoagulation for neovascularization of the iris after central retinal artery obstruction. Ophthalmology 1989; 96(1): 92-95.
33. Kotecha A, Spratt A, Ogunbowale L, dell'Omo R, Kulkarni A, Bunce C et al. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series. Arch Ophthalmol 2011; 129(2): 145-150.
34. Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006; 26(8): 871-876.
35. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114(5): 855-859.
36. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008; 28(5): 696-702.
37. Tsai JC, Feuer WJ, Parrish RK 2nd, Grajewski AL. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study. Ophthalmology 1995; 102(6): 887-892.
38. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL et al. Treatment outcomes in the tube versus trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol 2012; 153(5): 789-803 e2.
39. Shen CC, Salim S, Du H, Netland PA. Trabeculectomy versus Ahmed Glaucoma Valve implantation in neovascular glaucoma. Clin Ophthalmol 2011; 5: 281-286.
40. Wittstrom E, Holmberg H, Hvarfner C, Andreasson S. Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab. Eur J Ophthalmol 2012; 22(4): 563-574.
41. Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma 2009; 18(8): 632-637.
42. Costagliola C, Cipollone U, Rinaldi M, della Corte M, Semeraro F, Romano MR. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol. 2008; 66(5): 667-673.
43. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142(1): 158-160.
44. Martinez-Carpio PA, Bonafonte-Marquez E, Heredia-Garcia CD, Bonafonte-Royo S. [Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review]. Arch Soc Esp Oftalmol 2008; 83(10): 579-588.
45. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142(1): 155-158.
46. Simha A, Braganza A, Abraham L, Samuel P, Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev 2013; 10: CD007920.